Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct 3;27(149):180057.
doi: 10.1183/16000617.0057-2018. Print 2018 Sep 30.

Cardiovascular disease and COPD: dangerous liaisons?

Klaus F Rabe  1   2 , John R Hurst  3 , Samy Suissa  4   5
Affiliations
Review

Cardiovascular disease and COPD: dangerous liaisons?

Klaus F Rabe et al. Eur Respir Rev. .

Erratum in

Abstract

Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) frequently occur together and their coexistence is associated with worse outcomes than either condition alone. Pathophysiological links between COPD and CVD include lung hyperinflation, systemic inflammation and COPD exacerbations. COPD treatments may produce beneficial cardiovascular (CV) effects, such as long-acting bronchodilators, which are associated with improvements in arterial stiffness, pulmonary vasoconstriction, and cardiac function. However, data are limited regarding whether these translate into benefits in CV outcomes. Some studies have suggested that treatment with long-acting β2-agonists and long-acting muscarinic antagonists leads to an increase in the risk of CV events, particularly at treatment initiation, although the safety profile of these agents with prolonged use appears reassuring. Some CV medications may have a beneficial impact on COPD outcomes, but there have been concerns about β-blocker use leading to bronchospasm in COPD, which may result in patients not receiving guideline-recommended treatment. However, there are few data suggesting harm with these agents and patients should not be denied β-blockers if required. Clearer recommendations are necessary regarding the identification and management of comorbid CVD in patients with COPD in order to facilitate early intervention and appropriate treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: K.F. Rabe reports personal fees (consultant and speakers fees) from AstraZeneca, Boehringer Ingelheim, Novartis, Sanofi, Teva, Intermune, Chiesi Pharmaceuticals and Berlin Chemie, as well as grants from the Ministry of Education and Science, Germany, outside the submitted work. Conflict of interest: J. Hurst reports grants, personal fees and non-financial support from pharmaceutical companies that make medicines to treat COPD, outside the submitted work. Conflict of interest: S. Suissa reports grants and personal fees (board membership and research grant) from Novartis and Boehringer Ingelheim, and personal fees (lectures) from AstraZeneca, outside the submitted work.

Figures

FIGURE 1
FIGURE 1
Prevalence of comorbidities in pooled studies of patients with chronic obstructive pulmonary disease (COPD). Cardiovascular (CV) conditions and comorbidities are highlighted as orange bars and other comorbidities as yellow bars. Data are pooled from numerous studies and comorbidities with a prevalence (calculated as a weighted average based on study sample size) >5% are shown. IHD: ischaemic heart disease; HF: heart failure; AF: atrial fibrillation; CVA: cerebrovascular accident; AAA: abdominal aortic aneurysm; DVT: deep vein thrombosis; BPH: benign prostatic hypertrophy; PH: pulmonary hypertension; GERD: gastro-oesophageal reflux disease. #: comorbidities with a significant increase in mortality risk compared to patients with COPD without the comorbidity; : comorbidities with a significantly increased prevalence in patients with COPD compared with the general population. Reproduced and modified with permission from [3].
FIGURE 2
FIGURE 2
Association between cardiovascular disease, cardiovascular risk factors and chronic obstructive pulmonary disease (COPD) on mortality. Arrows and associated values indicate the impact of each comorbidity on the mortality risk of patients with COPD versus those patients with COPD alone. Where available, the reverse is also shown (the impact of COPD on the mortality risk of patients with each comorbidity versus those with the comorbidity alone). AF: atrial fibrillation; HF: heart failure; HR: hazard ratio; IHD: ischaemic heart disease; PH: pulmonary hypertension. #: HR was not significant after adjustment for confounding risk factors. Reproduced and modified with permission from [3].
FIGURE 3
FIGURE 3
Potential interactions between chronic obstructive pulmonary disease (COPD), cardiovascular (CV) risk and cardiovascular disease.
See this image and copyright information in PMC

References

    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2018 report). https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-rev... Date last accessed: November 28, 2017.
    1. Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 155–161. - PubMed
    1. Smith MC, Wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis 2014; 9: 871–888. - PMC - PubMed
    1. van den Akker M, Buntinx F, Knottnerus JA. Comorbidity or multimorbidity: what's in a name? A review of literature. Eur J Gen Pract 1996; 2: 65–70.
    1. Bhatt SP, Dransfield MT. AECOPD: acute exacerbations of chronic obstructive cardiopulmonary disease? Am J Respir Crit Care Med 2013; 188: 1046–1048. - PubMed

MeSH terms

Substances